Insmed Stock Surges 28.65% with 13.94 Billion Trading Volume Ranking 43rd in Market

On June 10, 2025, Insmed's trading volume reached 13.94 billion, marking a significant 915.99% increase from the previous day, placing it 43rd in the day's stock market rankings. Insmed (INSM) shares surged by 28.65%.

Insmed has announced that it will present detailed results from the Phase 2b study of TPIP in pulmonary arterial hypertension (PAH) and the open-label extension at future medical meetings. The company has reported positive topline results from the Phase 2b study of Treprostinil Palmitil Inhalation Powder (TPIP) as a once-daily therapy in patients with PAH. The study met its primary endpoint and all secondary efficacy endpoints, demonstrating a 35% placebo-adjusted reduction in pulmonary vascular resistance.

These results underscore TPIP's potential as a highly effective and well-tolerated once-daily prostanoid therapy for PAH patients. The study involved patients randomized to receive either TPIP or placebo for 16 weeks, showing a statistically significant reduction in pulmonary vascular resistance. Insmed's positive Phase 2b study results have garnered significant attention, highlighting the company's progress in developing innovative treatments for PAH.